IP Verse

Compositions And Uses For Treating Multiple Sclerosis - EP2653873

The patent EP2653873 was granted to Biogen Idec MA on Aug 24, 2022. The application was originally filed on Feb 7, 2008 under application number EP13169139A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2653873

BIOGEN IDEC MA
Application Number
EP13169139A
Filing Date
Feb 7, 2008
Status
Granted And Under Opposition
Jun 17, 2022
Grant Date
Aug 24, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (15)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BETAPHARM ARZNEIMITTELMay 21, 2025MAIWALDINTERVENTION
BIOGARANApr 20, 2023CASALONGAADMISSIBLE
DR SCHONApr 20, 2023DR SCHONADMISSIBLE
GLENMARK PHARMACEUTICALS EUROPEApr 19, 2023SCHLICHADMISSIBLE
KRAUS & LEDERER PARTGMBBApr 19, 2023KRAUS & LEDERER PARTGMBBADMISSIBLE
ACCORD HEALTHCAREApr 18, 2023BRAND MURRAY FULLERADMISSIBLE
ADALVOApr 14, 2023MAIWALDADMISSIBLE
TEVA PHARMACEUTICALSMar 6, 2023D YOUNGADMISSIBLE
STADA ARZNEIMITTELFeb 24, 2023KERNEBECKADMISSIBLE
G L PHARMAOct 10, 2022SONN PATENTANWALTEADMISSIBLE
ZENTIVA KSSep 23, 2022GRUNECKER PATENTADMISSIBLE
HEXALJul 21, 2022KRAUS & LEDERER PARTGMBBADMISSIBLE
POLPHARMAJul 21, 2022WICHMANNADMISSIBLE
GENERICS UK TRADING MYLANJul 20, 2022ELKINGTON AND FIFEADMISSIBLE
NEURAXPHARM ARZNEIMITTELJul 20, 2022TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (30) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20030433295-
DESCRIPTIONUS20040511564-
DESCRIPTIONUS4851439
DESCRIPTIONUS5149695
DESCRIPTIONUS5459667
DESCRIPTIONUS5650135
DESCRIPTIONUS6217847
DESCRIPTIONWO2006037342
OPPOSITIONEP0354921
OPPOSITIONEP2137537
OPPOSITIONEP2316430
OPPOSITIONEP2792349
OPPOSITIONUS2003018072
OPPOSITIONUS2012196931
OPPOSITIONUS6436992
OPPOSITIONUS7320999
OPPOSITIONUS8399514
OPPOSITIONWO0030622
OPPOSITIONWO2006037342
OPPOSITIONWO2006050730
OPPOSITIONWO2007005879
OPPOSITIONWO2007006307
OPPOSITIONWO2007006308
OPPOSITIONWO2007042034
OPPOSITIONWO2007042035
OPPOSITIONWO2008097596
OPPOSITIONWO9852549
OTHEREP2137537
OTHEREP2629097
OTHERWO2008097596

Non-Patent Literature (NPL) Citations (188) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ANDO ET AL., CELL IMMUNOL., (1989), vol. 124, pages 132 - 143-
DESCRIPTION- BAKER ET AL., J. NEUROIMMUNOL., (1990), vol. 28, page 261-
DESCRIPTION- BAXTER ET AL., AUTOIMMUNITY, (1991), vol. 9, no. 1, pages 61 - 67-
DESCRIPTION- BEN-NUN ET AL., EUR. J. IMMUNOL., (1981), vol. 11, pages 195 - 199-
DESCRIPTION- BUTTER ET AL., J. NEUROL. SCI., (1991), vol. 104, page 9-
DESCRIPTION- CALABRESE ET AL., J. NEUROSCI. RES., (2005), vol. 79, pages 509 - 521-
DESCRIPTION- CHAN ET AL., PNAS, (1996), vol. 93, pages 13943 - 13948-
DESCRIPTION- CHEN; KUNSCH, CURR. PHARM. DESIGNS, (2004), vol. 10, pages 879 - 891-
DESCRIPTION- DARLINGTON, CURR. OPIN. MOL. THER., (2005), vol. 7, no. 6, pages 598 - 603-
DESCRIPTION- DINKOVA-KOSTOVA ET AL., PNAS, (2001), vol. 98, pages 3404 - 09-
DESCRIPTION- DINKOVA-KOSTOVA ET AL., PNAS, (2005), vol. 102, no. 12, pages 4584 - 9-
DESCRIPTION- DRUGS R&D, (2005), vol. 6, no. 4, pages 229 - 30-
DESCRIPTION- ERCOLI ET AL., J. LMMUNOL., (2006), vol. 175, pages 3293 - 3298-
DESCRIPTION- EUGSTER ET AL., NAT. MED., (1999), vol. 29, pages 626 - 632-
DESCRIPTION- FREIREICH ET AL., CANCER CHEMOTHER. REPORTS, (1966), vol. 50, no. 4, pages 219 - 244-
DESCRIPTION- GAO ET AL., J. BIOL. CHEM.-
DESCRIPTION- GOLD ET AL., BRAIN, (2006), vol. 129, pages 1953 - 1971-
DESCRIPTION- HABIG ET AL., J. BIOL. CHEM., (1974), vol. 219, pages 7130 - 7139-
DESCRIPTION- HARRIS ET AL., ANN. NEUROL., (1991), vol. 29, page 548-
DESCRIPTION- HEMMINKI ET AL., J. NAT. CANCER INST., (2002), vol. 94, pages 741 - 749-
DESCRIPTION- HOFFMAN, LANCET ONCOL., (2002), vol. 3, pages 546 - 556-
DESCRIPTION- JI ET AL., LMMUNOL. REV., (1999), vol. 69, page 139-
DESCRIPTION- KERMONDE ET AL., BRAIN, (1990), vol. 113, page 1477-
DESCRIPTION- KRAFT ET AL., J. NEUROSCI., (2004), vol. 24, pages 1101 - 1112-
DESCRIPTION- KWAK ET AL., J. BIOL. CHEM., (2003), vol. 278, page 8135-
DESCRIPTION- KWAK ET AL., MOL. CELL BIOL., (2002), vol. 22, no. 9, pages 2883 - 2892-
DESCRIPTION- KWAK ET AL., MOL. CELL. BIOL., (2002), vol. 22, no. 9, pages 2883 - 2892-
DESCRIPTION- KWAK ET AL., MOL. MED., (2001), vol. 7, pages 135 - 145-
DESCRIPTION- LEE ET AL., J. BIOL. CHEM., (2003), vol. 278, no. 14, pages 12029 - 38-
DESCRIPTION- LIANG ET AL., MOL. THER., (2002), vol. 6, pages 73 - 82-
DESCRIPTION- LINKER ET AL., EUR. J. IMMUNOL., (2002), vol. 8, no. 6, pages 620 - 624-
DESCRIPTION- LODLE ET AL., TISSUE ENG., (2002), vol. 8, no. 5, pages 739 - 751-
DESCRIPTION- LUKE ET AL., J. VIROL., (2002), vol. 76, pages 12149 - 12161-
DESCRIPTION- MATTSON; CHENG, TRENDS IN NEUROSCI., (2006), vol. 29, no. 11, pages 632 - 639-
DESCRIPTION- MISGELD, HISTOCHEM. CELL BIOL., (2005), vol. 124, pages 189 - 196-
DESCRIPTION- MITTOO, COMB. CHEM. & HIGH THROUGHPUT SCREEN, (2006), vol. 9, pages 429 - 423-
DESCRIPTION- MUISWINKEI ET AL., NEUROBIOL. AGING, (2004), vol. 25, page 1253-
DESCRIPTION- MUISWINKEL, CURR. DRUG TARGETS--CNS. NEUROL. DISORD., (2005), vol. 4, pages 267 - 281-
DESCRIPTION- NIOI ET AL., MUTATION RES., (2004), vol. 555, pages 14 - 171-
DESCRIPTION- PROCHASKA ET AL., ANAL. BIOCHEM., (1988), vol. 169, pages 328 - 336-
DESCRIPTION- RAMOS-GOMEZ ET AL., J. NEUROSCI., (2004), vol. 24, no. 5, pages 1101 - 1112-
DESCRIPTION- RIEMEKASTEN ET AL., ARTHRITIS RHEUM., (2001), vol. 44, no. 10, pages 2436 - 2445-
DESCRIPTION- RUSHMORE ET AL., J. BIOL. CHEM., (1991), vol. 266, no. 18, pages 11632 - 9-
DESCRIPTION- SATOH ET AL., PNAS, (2006), vol. 103, no. 3, pages 768 - 773-
DESCRIPTION- SATOH, PNAS, (2006), vol. 103, no. 3, pages 768 - 773-
DESCRIPTION- SCHIMRIGK ET AL., EUR. J. NEUROL., (2006), vol. 13, no. 6, pages 604 - 10-
DESCRIPTION- SHI ET AL., PNAS, (2001), vol. 98, pages 12754 - 12759-
DESCRIPTION- SHIH ET AL., J. NEUROSCI., (2005), vol. 25, no. 44, pages 10321 - 35-
DESCRIPTION- SOBEL ET AL., J. IMMUNOL., (1984), vol. 132, pages 2393 - 2401-
DESCRIPTION- TRAUGOTT, CELL IMMUNOL., (1989), vol. 119, pages 114 - 129-
DESCRIPTION- TUNG ET AL., CANCER RES., (2000), vol. 60, pages 4953 - 4958-
DESCRIPTION- TUOHY ET AL., J. IMMUNOL., (1988), vol. 141, pages 1126 - 1130-
DESCRIPTION- TUOHY ET AL., J. LMMUNOL., (1988), vol. 141, pages 1126 - 1130-
DESCRIPTION- UNER ET AL., J. AUTOIMMUNE DISEASE, (1998), vol. 11, no. 3, pages 233 - 240-
DESCRIPTION- VAN HORSSEN ET AL., FREE RADICAL BIOL. & MED., (2006), vol. 41, pages 311 - 311-
DESCRIPTION- VAN MUISWINKEL, CURR. DRUG TARGETS CNS--NEUROL. DISORD., (2005), vol. 4, pages 267 - 281-
DESCRIPTION- WARREN ET AL., EUR. J. NEUROL., (2006), vol. 13, no. 8, pages 887 - 95-
DESCRIPTION- WIERINCKX ET AL., J. NEUROLMMUNOLOGY, (2005), vol. 166, pages 132 - 143-
DESCRIPTION- ZAMVIL ET AL., ANN. REV. IMMUNOL., (1990), vol. 8, pages 579 - 621-
DESCRIPTION- ZAMVIL ET AL., NATURE, (1985), vol. 317, pages 355 - 358-
OPPOSITION- 21st Annual Meeting of the Consortium of Multiple Sclerosis Centers, Washington DC, (20070530), page 43, 59-
OPPOSITION- Anonymous, "2007 RESEARCH AND DEVELOPMENT DAY", Biogen idec, (20070517), pages 1 - 6, XP093033285-
OPPOSITION- Anonymous, "BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis (INSPIRE)", Clinical Trial NCT02430532, (20170426), Clinical Trial NCT02430532, URL: https://classic.clinicaltrials.gov/ct2/show/NCT02430532?term=NCT02430532&draw=2&rank=1, XP093176385-
OPPOSITION- Anonymous, "Clinical Trials in Multiple Sclerosis 2007", National Multiple Sclerosis Society, (20070101), pages 1 - 7, XP093033279-
OPPOSITION- Anonymous, "Das MS-Register", MS-Register, Deutschen Multiple Sklerose Gesellschaft e.V. (DMSG), (20240625), pages 1 - 7, MS-Register, URL: https://www.msregister.de/ms-register/das-ms-register/, XP093178914-
OPPOSITION- Anonymous, "Dose Response Information to Support Drug Registration, CPMP/ICH/378/95", EMEA, (19941101), pages 1 - 10, EMEA, (20181120), XP055525263-
OPPOSITION- Anonymous, "Efficacy and Safety of BG00012 in MS", ClinicalTrials.gov; NCT00168701, (20230828), ClinicalTrials.gov; NCT00168701, URL: https://classic.clinicaltrials.gov/ct2/show/NCT00168701, (20240411), XP093150504-
OPPOSITION- Anonymous, "Exposure-Response Relationships - Study Design, Data Analysis and Regulatory Applications", Guidance for Industry, (20030401), Guidance for Industry, URL: https://www.fda.gov/media/71277/download, (20240411), XP093150476-
OPPOSITION- Anonymous, "Guidance for Industry, Exposure-Response Relationships - Study Design, Data Analysis, and Regulatory Applications", FDA, (20030401), XP055972682-
OPPOSITION- Anonymous, "ICH Topic E 4 - Dose Response Information to Support Drug Registration", European Medicines Agency; CPMP/ICH/378/95, (19941101), European Medicines Agency; CPMP/ICH/378/95, URL: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-4-dose-response-information-support-drug-registration-step-5_en.pdf, (20240411), XP093150470-
OPPOSITION- Anonymous, "ICH Topic E4 Dose Response Information to Support Drug Registration - NOTE FOR GUIDANCE ON DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION (CPMP/ICH/378/95) ", European Medicines Agency; CPMP/ICH/378/95, (19941101), European Medicines Agency; CPMP/ICH/378/95, (20240412), XP093150955-
OPPOSITION- Anonymous, "Multiple sclerosis", Wikipedia, the free encyclopedia, (20170503), Wikipedia, the free encyclopedia , URL: http://en.wikipedia.org:80/wiki/Multiple_sclerosis, XP093190471-
OPPOSITION- Anonymous, "Neuroprotection", MS Society - News and Research - Explore our research - Emerging research and treatments, MS Society, (20240621), pages 1 - 3, MS Society - News and Research - Explore our research - Emerging research and treatments, URL: https://www.mssociety.org.uk/research/explore-our-research/emerging-research-and-treatments/neuroprotection, XP093177860-
OPPOSITION- Anonymous, "Trial from ANZCTR, Trial ID ACTRN12607000124437", ANZCTR, (20070212), pages 1 - 4, XP093033282-
OPPOSITION- Anonymous, "TRIAL WATCH : '' Phase III success for Biogen's oral multiple sclerosis therapy ", Nature Reviews Drug Discovery, (20110601), vol. 10, page 404, XP093027348-
OPPOSITION- Anonymous, "View of NCT00420212, Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis", ClinicalTrials, (20071228), pages 1 - 4, XP093033371-
OPPOSITION- Anonymous, "View of NCT00451451, Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis", ClinacalTrials, (20080102), pages 1 - 4, XP093033373-
OPPOSITION- ARASTOO A.A. ; AHMADI A. ; ZAHEDNEJAD SH., "THE COMPARISION OF EFFECT OF 8 WEEKS AEROBIC AND YOGA TRAINING ON PHYSIOLOGICAL COST INDEX IN MULTIPLE SCLEROSIS PATIENTS", JUNDISHAPUR SCIENTIFIC MEDICAL JOURNAL, (20101130), vol. 10, no. 2, ISSN 1026-8960, pages 153 - 162, XP009543336-
OPPOSITION- Biogen Idec, "Oral compound BG-12 achieves primary endpoint in phase II study of relapsing-remitting multiple sclerosis; treatment with BG-12 led to statistically significant reductions in MRI measures", Biogen Idec Press Release, (20060530), XP055475131-
OPPOSITION- "Committee for Medicinal Products for Human Use (CHMP), Assessment report Tecfidera", EMA, (20131126), pages 1 - 136, URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002601/WC500162070.pdf, (20140415), XP055114136-
OPPOSITION- "Committee for Medicinal Products for Human Use (CHMP), Assessment report Tecfidera", EMA, (20131126), pages 1 - 136, URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002601/WC500162070.pdf, XP055114136-
OPPOSITION- De-Hyung Lee, Ralf A. Linker, Ralf Gold, "Spotlight on Fumarates", INTERNATIONAL MS JOURNAL, CAMBRIDGE MEDICAL PUBLISHERS, WORTHING, GB, GB , (20080101), vol. 15, no. 1, ISSN 1352-8963, pages 12 - 18, XP008164548-
OPPOSITION- D. M. Wingerchuk, B. G. Weinshenker, "Chapter 3: Unusual presentations and variants of idiopathic central nervous system demyelinating diseases", Multiple sclerosis: A comprehensive Text, Elsevier Saunders, (20080919), pages 24 - 42, ISBN 978-0-7020-2811-3, XP009555104-
OPPOSITION- Efficacy and Safety of BG 00012 in MS, (20050914), URL: https://www.dinicaitria!s.c)ov/archive/NCT00168701-
OPPOSITION- "Efficacy and safety of oral BG00012 in relapsing-remitting multiple sclerosis (DEFINE)", pages 1 - 2, URL: http://www.clinicaltrials.gov/ct2/show/NCT00420212?term=bg00012&rank=1, (20080919), XP002496491-
OPPOSITION- El-Moslimany H., D F. D. Lublin, Cedric S. Raine, Henry F. Mcfarland, Reinhard Hohlfeld, "2. Clinical features in multiple sclerosis", Multiple Sclerosis A Comprehensive Text, Elsevier, (20080101), pages 10 - 12, 100-116, XP093182927-
OPPOSITION- Ema Chmp, "Tecfidera", Assessment report - EMA/800904/2013 Corr. 1, (20131126), pages 1 - 126, Assessment report - EMA/800904/2013 Corr. 1, URL: https://www.ema.europa.eu/en/documents/assessment-report/tecfidera-epar-public-assessment-report_en.pdf, (20220301), XP055896299-
OPPOSITION- Ema, "Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis", EMA/CHMP/771815/2011, Rev. 2, (20150326), pages 1 - 20, XP093176382-
OPPOSITION- Ema, "Ocrevus", Assessment Report EMA/790835/2017, (20171109), pages 1 - 180, XP093176386-
OPPOSITION- EMEA, "Dose Response Information to Support Drug Registration", CPMP/ICH/378/95, (19941101), pages 1 - 10, XP055525263-
OPPOSITION- Faissner Simon, "ZWEITGENERATION-FUMARAT: DIROXIMELFUMARAT FÜR DIE MULTIPLE SKLEROSE THERAPIE ZUGELASSEN", MS-Therapien, (20211202), pages 1 - 3, MS-Therapien, URL: https://www.dmsg.de/news/detailansicht/zweitgeneration-fumarat-diroximelfumarat-fuer-die-multiple-sklerose-therapie-zugelassen, (20220802), XP055948237-
OPPOSITION- Fox, Et Al, "31 - Dimethyl fumarate to treat multiple sclerosis from Section III - Clinical trials of multiple sclerosis therapies", Multiple Sclerosis Therapeutics, (20111205), pages 387 - 392, XP093028700-
OPPOSITION- Fox Robert J., "BG00012 — A Novel Oral Therapy in Development for the Treatment of Multiple Sclerosis", US Neurological Disease, Touch Briefings, (20070101), no. 2, pages 32 - 36, XP093033375-
OPPOSITION- Fox Robert J., Gold Ralf, "Clinical trials of multiple sclerosis therapies (Section III) Dimethyl fumarate to treat multiple sclerosis (Chap. 31)", MULTIPLE SCLEROSIS THERAPEUTICS FOURTH EDITION, US, Cambridge University, (20110101), pages 387 - 392, ISBN 978-0-521-76627-2, XP093142028-
OPPOSITION- Fred D Lublin, "Defining the clinical course of multiple sclerosis The 2013 revisions", Neurology, (20140715), vol. 83, no. 3, pages 278 - 286, XP093166706-
OPPOSITION- Fumaderm Label, product Characteristics-
OPPOSITION- GOLD et al., "Safety of a novel oral single-agent fumarate, BG 00012, in patients with relapsing-remitting multiple sclerosis: result of a phase 2 study", Journal of Neurology, (20060500), page P573, XP009157336-
OPPOSITION- Gold R. et al, "Two phase 3 studies to determine the efficacy and safety of BG00012, a novel, oral fumaric acid derivative, in patients with relapsing multiple sclerosis", 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) & 12th Annual Conference of Rehabilitation in MS (RIMS), (20071013), pages 1 - 1, XP093033368-
OPPOSITION- Gold R., Fox R, Dawson K, O'neill G, Yang M, Panzara M, "Two phase 3 studies to determine the efficacy and safety of BG00012, a novel, oral fumaric acid derivative, in patients with relapsing multiple sclerosis", 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) & 12th Annual Conference of Rehabilitation in MS (RIMS), (20071013), XP093151092-
OPPOSITION- Gold R., R. Fox, K. Dawson, G. O’neill, M. Yang, M. Panzara, "Two phase 3 studies to determine the efficacy and safety of BG00012, a novel, oral fumaric acid derivative, in patients with relapsing multiple sclerosis", 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) & 12th Annual Conference of Rehabilitation in MS (RIMS), (20071013), pages 1 - 1, XP093033368-
OPPOSITION- Guidance for Industry, Exposure-Response Relationships - Study Design, Data Analysis, and Regulatory Applications, (20030400), XP055972682-
OPPOSITION- KAPPOS et al., 16th Meeting of European Neurological Society, (20060530), XP055475133-
OPPOSITION- KAPPOS et al., "BG 00012, a novel oral fumarate, is effective in patients with relapsing- remitting multiple sclerosis", Sage Journals: Multiple Sclerosis, (20060900), vol. 12, page P325, XP009157337-
OPPOSITION- KAPPOS et al., "Efficacy of a novel oral single-agent fumarate, BG 00012, in patients with relapsing-remitting multiple sclerosis: results of a phase II study", 16th Meeting of the European Neurological Society, (20060530), XP055475133-
OPPOSITION- Kappos L, Miller DH, MacManus DG, et al., "BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis", Multiple Sclerosis Journal, Sage, US , (20060101), vol. 12, no. Suppl. 1, ISSN 1352-4585, page S85, XP009157337-
OPPOSITION- Kappos L, Miller DH, MacManus DG, et al., "BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis", Multiple Sclerosis Journal, Sage, US, US , (20060101), vol. 12, no. Suppl. 1, ISSN 1352-4585, page S85, XP009157337-
OPPOSITION- LEE, DE -HYUNG et al., "Spotlight on Fumarates", The International MS Journal, (20080000), vol. 15, pages 12 - 18, XP008164548-
OPPOSITION- LIST OF CLINICAL TRIALS IN MULTIPLE SCLEROSIS, pgs 36-37, 2007-
OPPOSITION- L. Kappos et al, "Efficacy of a novel oral single-agent Fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase II study", Presentation, (20060530), page 12pp, XP055475133-
OPPOSITION- L. Kappos et al., "Efficacy of a novel oral single-agent Fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase II study", Presentation, (20060530), page 12pp, XP055475133-
OPPOSITION- L. Kappos, Et Al.,, "Efficacy of a novel oral single-agent Fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase II study", Presentation, (20060530), page 12pp, XP055475133-
OPPOSITION- L. Kappos, P. Calabresi, R. Hohlfeld, P.O Connor, C. Polman, S. Aradhye, "P569 : Design of a randomised, placebo-controlled study of oral fingolimod (FTY720) in relapsing-remitting multiple sclerosis", Journal of Neurology, (20060101), vol. 253, no. Suppl.2, pages II/2, II/143 - II/144, XP055976624-
OPPOSITION- Mccue Justin, "BIOGEN IDEC ANNOUNCES POSITIVE TOP-LINE RESULTS FROM SECOND PHASE 3 TRIAL INVESTIGATING ORAL BG-12 (DIMETHYL FUMARATE) IN MULTIPLE SCLEROSIS ", BIOGEN IDEC, WESTON, Mass, WESTON, Mass, (20111026), pages 1 - 3, BIOGEN IDEC, (20230227), XP093027354-
OPPOSITION- Ntd, "NTD Report Biogen Dimethyl fumarate in PPMS 20.02.2024. Primary Progressive Multiple Sclerosis in Germany", Neuro Trans Data - NTD Report, (20240220), pages 1 - 9, Neuro Trans Data - NTD Report, XP093166713-
OPPOSITION- O. Andersen, "Chapter: Natural history of multiple sclerosis", O. Andersen, Raine, Cedric S., Multiple sclerosis: A comprehensive Text, Elsevier Saunders, (20080919), pages 100 - 120, ISBN 978-0-7020-2811-3, XP009555105-
OPPOSITION- Ontaneda Daniel, Fox Robert J, Chataway Jeremy, "Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives", The Lancet Neurology, (20150201), vol. 14, no. 2, pages 208 - 223, XP093177167-
OPPOSITION- Proudfoot Stuart ; Collett John, "Dosage regimens", Proudfoot Stuart ; Collett John, Aulton E. Michael, Pharmaceutics - The Science of Dosage Form Design second edition, Elsiver, (2002), pages 275 - 288, Chapter 19, XP055397036-
OPPOSITION- "Questions and answers on the ongoing review of Gilenya (fingolimod", EMA/43541/2012, (20120119), pages 1 - 2-
OPPOSITION- R.Gold, E. Havrdova, L.Kappos,V. Limmroth, D. Miller, C. Polman, M. Yang, M. Eraksoy, E. Meluzinova, I. Rektor, G. N. O�Neill, "P573 Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, SPRINGER VERLAG, BERLIN., DE, DE , (20060501), vol. 253, no. Suppl. 2, ISSN 0340-5354, pages II 144 - II 145, XP009157336-
OPPOSITION- Sheridan C., "Safely profiles come to fore as more drugs approach MS market", NATURE BIOTECHNOLOGY, (20210101), vol. 30, no. 1, pages 6 - 8, XP093033683-
OPPOSITION- "Tecfidera 240 mg Summary of Product Characteristics", ema-
OPPOSITION- The Multiple Sclerosis Trust, "New MS drugs on the horizon - Dr Martin Duddy", Youtube, (20171212), Youtube, URL: https://www.youtube.com/watch?v=Iof3ag2eB50, XP093206054-
OPPOSITION- U.S. Fda, "Exposure-Response Relationships — Study Design, Data Analysis, and Regulatory Applications", Guidance for Industry, (20030401), URL: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072109.pdf, XP055366750-
OPPOSITION- "View of clinical trial NCT00168701", (20050914), (20160421), XP055267335-
OPPOSITION- Vindeirinho Joana, "Tecfidera Has No Impact on PPMS Progression After 2 Years: Trial Data - Patients in Phase 2 trial remain stable with or without treatment", (20221214), URL: https://multiplesclerosisnewstoday.com/news-posts/2022/12/14/no-effect-tecfidera-ppms-progression-after-2-years-trial-finds/#:~:text=Continuous%20treatment%20with%20Tecfidera%20(dimethyl,started%20treatment%20after%20one%20year., XP093175860-
OPPOSITION- Wierinckx, A. ; Breve, J. ; Mercier, D. ; Schultzberg, M. ; Drukarch, B. ; Van Dam, A.M., "Detoxication enzyme inducers modify cytokine production in rat mixed glial cells", Journal of Neuroimmunology, ELSEVIER SCIENCE PUBLISHERS BV., NL, NL , (20050901), vol. 166, no. 1-2, ISSN 0165-5728, pages 132 - 143, XP027673157-
OPPOSITION- Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H. Smith, "Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial", Annals of Neurology, John Wiley and Sons, Boston , US, Boston , US , (20090909), vol. 66, no. 4, doi:10.1002/ana.21867, ISSN 0364-5134, pages 460 - 471, XP071639199
OPPOSITION- Scolding Neil, "Future Therapies for Progressive Multiple Sclerosis", Progressive Multiple Sclerosis, Springer London, (20130813), pages 221 - 243, doi:10.1007/978-1-4471-2395-8_10, ISBN 978-1-4471-2394-1, XP093177844
OPPOSITION- W Kruse, W Eggert-Kruse, J Rampmaier, B Runnebaum , E. Weber , "Dosage frequency and drug-compliance behavior", European Journal of Clinical Pharmacology, Springer Berlin Heidelberg, Berlin/Heidelberg, Berlin/Heidelberg, (19911201), vol. 41, doi:10.1007/BF00314990, ISSN 0031-6970, pages 589 - 592, XP009553698
OPPOSITION- Hauray Boris, "From Regulatory Knowledge to Regulatory Decisions: The European Evaluation of Medicines", Minerva, Springer Netherlands, Dordrecht, Dordrecht , (20170530), vol. 55, no. 2, doi:10.1007/s11024-017-9323-3, ISSN 0026-4695, pages 187 - 208, XP036260582
OPPOSITION- Dimitriou Nikolaos G., Meuth Sven G., Martinez-Lapiscina Elena H., Albrecht Philipp, Menge Til, "Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease", CNS DRUGS, ADIS INTERNATIONAL, AUCKLAND, NZ , (20230101), vol. 37, no. 1, doi:10.1007/s40263-022-00977-3, ISSN 1172-7047, pages 69 - 92, XP093188392
OPPOSITION- Lamb Yvette N., Hartung H.-P, , "Ocrelizumab: A Review in Multiple Sclerosis", Drugs, Adis International Ltd., NZ, NZ , (20220201), vol. 82, no. 3, doi:10.1007/s40265-022-01672-9, ISSN 0012-6667, pages 323 - 334, XP093177847
OPPOSITION- Bar-Or Amit, Thanei Gian-Andrea, Harp Christopher, Bernasconi Corrado, Bonati Ulrike, Cross Anne H., Fischer Saloumeh, Gaetano Laura, Hauser Stephen L., Hendricks Robert, Kappos Ludwig, Kuhle Jens, Leppert David, Model Fabian, Sauter Annette, Koendgen Harold, Jia Xiaoming, Herman Ann E., "Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials", EBioMedicine, Elsevier BV, NL, NL , (20230701), vol. 93, doi:10.1016/j.ebiom.2023.104662, ISSN 2352-3964, page 104662, XP093138813
OPPOSITION- MAJKUTEWICZ, "Dimethyl fumarate: A review of preclinical efficacy in models of neurodegenerative disease", European Journal of Pharmacology, (20220000), vol. 926, no. 175025, doi:10.1016/j.ejphar.2022.175025, pages 1 - 15, XP087077704
OPPOSITION- Wierinckx, A. Breve, J. Mercier, D. Schultzberg, M. Drukarch, B. Van Dam, A.M., "Detoxication enzyme inducers modify cytokine production in rat mixed glial cells", Journal of Neuroimmunology, ELSEVIER SCIENCE PUBLISHERS BV., NL, NL , (20050901), vol. 166, no. 1-2, doi:10.1016/j.jneuroim.2005.05.013, ISSN 0165-5728, pages 132 - 143, XP005000427
OPPOSITION- WIERINCKX et al., "Detoxication enzyme inducers modify cytokine production in rat mixed glial cell s", JOURNAL OF NEUROIMMUNOLOGY, (20050901), vol. 166, no. 1-2, doi:10.1016/j.jneuroim.2005.05.013, pages 132 - 143, XP005000427
OPPOSITION- Talbot J.; Højsgaard Chow H.; Holm Hansen R.; von Essen M. Rode; Sellebjerg F., "Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS", Journal of Neuroimmunology, ELSEVIER SCIENCE PUBLISHERS BV., NL, NL , (20211022), vol. 361, doi:10.1016/j.jneuroim.2021.577756, ISSN 0165-5728, XP086870093
OPPOSITION- Peterson John W., Trapp Bruce D., "Neuropathobiology of multiple sclerosis", Neurologic Clinics, Elsevier Science., US, US , (20050201), vol. 23, no. 1, doi:10.1016/j.ncl.2004.09.008, ISSN 0733-8619, pages 107 - 129, XP009555103
OPPOSITION- Wolinsky Jerry S, "The diagnosis of primary progressive multiple sclerosis", JOURNAL OF NEUROLOGICAL SCIENCES., ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM., NL, NL , (20030215), vol. 206, no. 2, doi:10.1016/S0022-510X(02)00346-5, ISSN 0022-510X, pages 145 - 152, XP093177834
OPPOSITION- Sorensen, P.S. ; Sellebjerg, F., "Oral fumarate for relapsing-remitting multiple sclerosis", The Lancet, AMSTERDAM, NL , (20081025), vol. 372, no. 9648, doi:10.1016/S0140-6736(08)61605-0, ISSN 0140-6736, pages 1447 - 1448, XP025584398
OPPOSITION- for the BG-12 Phase IIb Study Investigators ; Kappos, L. ; Gold, R. ; Miller, D.H. ; MacManus, D.G. ; Havrdova, E. ; Limmroth, V. ; Polman, C.H. ; Schmierer, K. ; Yousry, T.A. ; Yang, M. ; Eraksoy, M. ; Meluzinova, E. ; Rektor, I. ; Dawson, K.T. ; Sandrock, A.W. ; O'Neill, G.N., "Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20081025), vol. 372, no. 9648, doi:10.1016/S0140-6736(08)61619-0, ISSN 0140-6736, pages 1463 - 1472, XP025584415
OPPOSITION- KAPPOS et al., "Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study", THE LANCET, (20181025), vol. 372, pages 1463 - 142, XP002718801
OPPOSITION- Kappos L et al, "Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebp-controlled phase IIb study", The Lancet, AMSTERDAM, NL , (20081025), vol. 372, no. 9648, doi:10.1016/S0140-6736(08)61619-0, ISSN 0140-6736, pages 1463 - 1472, XP002718801
OPPOSITION- Kappos L. et al, "Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebp-controlled phase IIb study", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20081025), vol. 372, no. 9648, doi:10.1016/S0140-6736(08)61619-0, ISSN 0140-6736, pages 1463 - 1472, XP002718801
OPPOSITION- Kappos L, Gold R, Miller D H, Macmanus D G, Havrdova E, Limmroth V, Polman C H, Schmierer K, Yousry T A, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson K T, Sandrock A W, O'Neill G N; BG-12 Phase IIb Study Investigators., "Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebp-controlled phase IIb study", The Lancet, ELSEVIER, AMSTERDAM, NL , (20081025), vol. 372, no. 9648, doi:10.1016/S0140-6736(08)61619-0, ISSN 0140-6736, pages 1463 - 1472, XP002718801
OPPOSITION- Kappos L, Gold R, Miller D H, Macmanus D G, Havrdova E, Limmroth V, Polman C H, Schmierer K, Yousry T A, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson K T, Sandrock A W, O'Neill G N; BG-12 Phase IIb Study Investigators., "Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebp-controlled phase IIb study", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20081025), vol. 372, no. 9648, doi:10.1016/S0140-6736(08)61619-0, ISSN 0140-6736, pages 1463 - 1472, XP002718801
OPPOSITION- KILLESTEIN et al., "Oral treatment for multiple sclerosis", LANCET NEUROLOGY, (20111110), doi:10.1016/S1474-4422(11)70228-9, pages 1026 - 1034, XP009164310
OPPOSITION- Killestein Joep; Rudick Richard A; Polman Chris H, "Oral treatment for multiple sclerosis", The Lancet Neurology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20111101), vol. 10, no. 11, doi:10.1016/S1474-4422(11)70228-9, ISSN 1474-4422, pages 1026 - 1034, XP009164310
OPPOSITION- Chataway Jeremy; Williams Thomas; Li Vivien; Marrie Ruth Ann; Ontaneda Daniel; Fox Robert J, "Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges", The Lancet Neurology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20240214), vol. 23, no. 3, doi:10.1016/S1474-4422(24)00027-9, ISSN 1474-4422, pages 277 - 301, XP087468861
OPPOSITION- Tomas Olsson, "Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis", Nature Reviews Neurology, Nature Publishing Group UK, London, London, (20170101), vol. 13, no. 1, doi:10.1038/nrneurol.2016.187, ISSN 1759-4758, pages 25 - 36, XP093166710
OPPOSITION- N.H.R. Litjens; P.H. Nibbering; A.J. Barrois; T.P.L. Zomerdijk; A.C. Van Den Oudenrijn; K.C. Noz; M. Rademaker; P.H. Van De Meide; J.T. Van Dissel; B. Thio, "Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines", British Journal of Dermatology, Hoboken, USA, (20030325), vol. 148, no. 3, doi:10.1046/j.1365-2133.2003.05153.x, ISSN 0007-0963, pages 444 - 451, XP071157365
OPPOSITION- J. Phillips, Robert Fox, "BG-12 in Multiple Sclerosis", Seminars in Neurology, vol. 33, no. 01, doi:10.1055/s-0033-1343796, ISSN 02718235, pages 056 - 065, XP055166863
OPPOSITION- J. Phillips, Robert Fox, "BG-12 in Multiple Sclerosis", Seminars in Neurology, vol. 33, no. 1, doi:10.1055/s-0033-1343796, ISSN 02718235, pages 56 - 65, XP055166863
OPPOSITION- Xavier Montalban, "Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis", The New England journal of medicine, Massachusetts Medical Society, US, US , (20170119), vol. 376, no. 3, doi:10.1056/NEJMoa1606468, ISSN 0028-4793, pages 209 - 220, XP093166692
OPPOSITION- R. Gold, "Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research", Brain, Oxford University Press, GB, GB , vol. 129, no. 8, doi:10.1093/brain/awl075, ISSN 0006-8950, pages 1953 - 1971, XP055743243
OPPOSITION- LITJENS N H R, ET AL., "PHARMACOKINETICS OF ORAL FUMARATES IN HEALTHY SUBJECTS", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, GB , (20041001), vol. 58, no. 4, doi:10.1111/j.1365-2125.2004.02145.x, ISSN 0306-5251, pages 429 - 432, XP008047032
OPPOSITION- SCHILLING, S. et al., "Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration", Clinical and Experimental Immunology, (20060000), vol. 145, no. 1, doi:10.1111/j.1365-2249.2006.03094.x, pages 101 - 107, XP071088420
OPPOSITION- S. Schilling; S. Goelz; R. Linker; F. Luehder; R. Gold, "Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration", Clinical and experimental immunology, Wiley-Blackwell Publishing Ltd., GB, GB , (20060601), vol. 145, no. 1, doi:10.1111/j.1365-2249.2006.03094.x, ISSN 0009-9104, pages 101 - 107, XP071088420
OPPOSITION- S. Schilling; S. Goelz; R. Linker; F. Luehder; R. Gold, "Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, Wiley-Blackwell Publishing Ltd., GB, GB , (20060601), vol. 145, no. 1, doi:10.1111/j.1365-2249.2006.03094.x, ISSN 0009-9104, pages 101 - 107, XP071088420
OPPOSITION- SCHIMRIGK et al., "Oral fumaric acid esters for the Corresponds to TM7 as filed treatment of active multiple sclerosis: an open-label, by Neuraxpharm and by D5 baseline-controlled pilot study", European Journal of filed by Hexal Neurology, (20060606), vol. 13, no. 6, pages 604 - 610, XP002496484
OPPOSITION- SCHIMRIGK et al., "Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study", European Journal of Neurology, (20050000), vol. 13, no. 6, doi:10.1111/j.1468-1331.2006.01292.x, pages 604 - 610, XP002496537
OPPOSITION- SCHIMRIGK et al., "Oral fumaric acid esters for the treatment of active multiple sclerosis: An open-label, baseline-controlled pilot study", European Journal of Neurology, (20060000), vol. 13, no. 6, doi:10.1111/j.1468-1331.2006.01292.x, pages 604 - 10, XP002496537
OPPOSITION- SCHIMRIGK et al., "Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study", European Journal of Neurology, (20060600), vol. 13, no. 6, doi:10.1111/j.1468-1331.2006.01292.x, pages 604 - 610, XP002496537
OPPOSITION- SCHIMRIGK S. et al., "Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study", E uropean Journal of Neurology, (20060000), vol. 13, doi:10.1111/j.1468-1331.2006.01292.x, pages 604 - 610, XP002496537
OPPOSITION- SCHIMRIGK S. ET AL., "Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study", EUROPEAN JOURNAL OF NEUROLOGY, GB , (20060101), vol. 13, doi:10.1111/j.1468-1331.2006.01292.x, ISSN 1351-5101, pages 604 - 610, XP002496484
OPPOSITION- SCHIMRIGK S ET AL, "Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study", EUROPEAN JOURNAL OF NEUROLOGY, RAPID SCIENCE PUBLISHERS., GB, GB , (20060601), vol. 13, no. 6, doi:10.1111/j.1468-1331.2006.01292.x, ISSN 1351-5101, pages 604 - 610, XP002496537
OPPOSITION- Menon Suresh, Shirani Afsaneh, Zhao Yinshan, Oger Joel, Traboulsee Anthony, Freedman Mark S, Tremlett Helen, "Characterising aggressive multiple sclerosis", JOURNAL OF NEUROLOGY NEUROSURGERY & PSYCHIATRY., BMJ Publishing Group, GB, GB , (20131101), vol. 84, no. 11, doi:10.1136/jnnp-2013-304951, ISSN 0022-3050, pages 1192 - 1198, XP093188381
OPPOSITION- Lunde Hanne Marie, Assmus Jörg, Myhr Kjell-Morten, Bø Lars, Grytten Nina, "Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study", JOURNAL OF NEUROLOGY NEUROSURGERY & PSYCHIATRY., BMJ Publishing Group, GB, GB , (20170801), vol. 88, no. 8, doi:10.1136/jnnp-2016-315238, ISSN 0022-3050, pages 621 - 625, XP093177170
OPPOSITION- Anna Karin Hedström, "Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis", JOURNAL OF NEUROLOGY NEUROSURGERY & PSYCHIATRY., BMJ Publishing Group, GB, GB , (20210513), vol. 92, no. 10, doi:10.1136/jnnp-2020-325688, ISSN 0022-3050, pages 1096 - 1102, XP093166707
OPPOSITION- Nieboer, Et Al, "Fumaric Acid Therapy in Psoriasis: A Double-Blind Comparison between Fumaric Acid Compound Therapy and Monotherapy with Dimethylfumaric Acid Ester", Dermatologica, (19900101), vol. 181, doi:10.1159/000247856, pages 33 - 37, XP055365695
OPPOSITION- Scalfari Antonio, "MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Yes", Multiple Sclerosis Journal, Sage, US, US , (20210601), vol. 27, no. 7, doi:10.1177/13524585211001789, ISSN 1352-4585, pages 1002 - 1004, XP093177862
OPPOSITION- Strassburger-Krogias Katrin, Ellrichmann Gisa; Krogias Christos; Altmeyer Peter; Chan Andrew; Gold Ralf, "Fumarate treatment in progressive forms of multiple sclerosis: first results of a singlecenter observational study", Therapeutic Advances in Neurological Disorders, (20140101), vol. 7, no. 5, doi:10.1177/1756285614544466Therapeutic, pages 232 - 238, XP093176377
OPPOSITION- Moreira Ferreira Vanessa, Liu Yanqing; Healy Brian C; Stankiewicz James M; ; , "Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis", Multiple Sclerosis Journal - Experimental, Translational and Clinical, (20210401), vol. 7, no. 2, doi:10.1177/20552173211010832, ISSN 2055-2173, XP093176379
OPPOSITION- Mancardi Giovanni Luigi, Murialdo Alessandra, Rossi Paolo, Gualandi Francesca, Martino Gianvito, Marmont Alberto, Ciceri Fabio, Schenone Angelo, Parodi Roberto Carlo, Capello Elisabetta, Comi Giancarlo, Uccelli Antonio, "Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis", Multiple Sclerosis Journal, Sage, US, US , (20050601), vol. 11, no. 3, doi:10.1191/1352458505ms1181cr, ISSN 1352-4585, pages 367 - 371, XP093188389
OPPOSITION- Timothy L. Vollmer, "Multiple Sclerosis Phenotypes as a Continuum : The Role of Neurologic Reserve", Neurology: Clinical Practice, Lippincott Williams & Wilkins, (20210801), vol. 11, no. 4, doi:10.1212/CPJ.0000000000001045, ISSN 2163-0402, pages 342 - 351, XP093166695
OPPOSITION- Helene Højsgaard Chow, "Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis : A Randomized, Controlled Trial", NEUROLOGY: NEUROIMMUNOLOGY & NEUROINFLAMMATION, American Academy of Neurology, US, US , (20210824), vol. 8, no. 5, doi:10.1212/NXI.0000000000001037, ISSN 2332-7812, pages 1 - 10, XP093166704
OPPOSITION- Von Essen Marina, Talbot Jacob; Hansen Rikke Holm Holm; Chow Helene Højsgaard; Lundell Henrik; Siebner Hartwig Roman; Sellebjerg Finn, "Intrathecal CD8 + CD20 + T Cells in Primary Progressive Multiple Sclerosis", NEUROLOGY: NEUROIMMUNOLOGY & NEUROINFLAMMATION, American Academy of Neurology, US, US , (20230901), vol. 10, no. 5, doi:10.1212/NXI.0000000000200140, ISSN 2332-7812, XP093176375
OPPOSITION- Kapoor Raju, Smith Kathryn E., Allegretta Mark, Arnold Douglas L., Carroll William, Comabella Manuel, Furlan Roberto, Harp Christopher, Kuhle Jens, Leppert David, Plavina Tatiana, Sellebjerg Finn, Sincock Caroline, Teunissen Charlotte E., Topalli Ilir, Von Raison Florian, Walker Elizabeth, Fox Robert J., "Serum neurofilament light as a biomarker in progressive multiple sclerosis", Neurology, Lippincott Williams & Wilkins, (20200908), vol. 95, no. 10, doi:10.1212/WNL.0000000000010346, ISSN 0028-3878, pages 436 - 444, XP093177163
OPPOSITION- Shih Andy Y., Johnson Delinda A., Wong Gloria, Kraft Andrew D., Jiang Lei, Erb Heidi, Johnson Jeffrey A., Murphy Timothy H., "Coordinate Regulation of Glutathione Biosynthesis and Release by Nrf2-Expressing Glia Potently Protects Neurons from Oxidative Stress", THE JOURNAL OF NEUROSCIENCE, US , (20030415), vol. 23, no. 8, doi:10.1523/JNEUROSCI.23-08-03394.2003, ISSN 0270-6474, pages 3394 - 3406, XP055950977
OPPOSITION- GOLD. R, "Oral Therapies for Multiple Sclerosis: A Review of Agents In Phase III Developments or Recently Approved", CNS DRUGS, (20110000), vol. 25, no. 1, doi:10.2165/11539820-000000000-00000, pages 37 - 52, XP008139191
OPPOSITION- Reiner W. Heckl, "8. Verlauf", Multiple Sklerose Klinik - Differentialdiagnose - Behandlung, Stuttgart • New York, Georg Thieme Verlag, (19940101), pages 95 - 105, doi:v, ISBN 978-3-13-114501-7, XP093166700
OTHER- Biogen Idec, "Oral compound BG-12 achieves primary endpoint in phase II study of relapsing-remitting multiple sclerosis; treatment with BG-12 led to statistically significant reductions in MRI measures", Biogen Idec Press Release, (20060530), XP055475131-
OTHER- L. KAPPOS, "Efficacy of a novel oral single-agent Fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase II study", Presentation, (20060530), page 12pp, XP055475133-
OTHER- Shih Andy Y., Johnson Delinda A., Wong Gloria, Kraft Andrew D., Jiang Lei, Erb Heidi, Johnson Jeffrey A., Murphy Timothy H., "Coordinate Regulation of Glutathione Biosynthesis and Release by Nrf2-Expressing Glia Potently Protects Neurons from Oxidative Stress", THE JOURNAL OF NEUROSCIENCE, Society for Neuroscience, US, US , (20030415), vol. 23, no. 8, doi:10.1523/JNEUROSCI.23-08-03394.2003, ISSN 0270-6474, pages 3394 - 3406, XP055950977
SEARCH- GOLD R ET AL, "Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, SPRINGER VERLAG, BERLIN, DE, (20060501), vol. 253, no. Suppl. 2, ISSN 0340-5354, pages II144 - II145, XP009157336 [X] 1-21 * the whole document *-
SEARCH- KAPPOS L ET AL, "BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis", MULTIPLE SCLEROSIS, SAGE PUBLICATIONS, BASINGSTOKE, GB, (20060101), vol. 12, no. Suppl. 1, ISSN 1352-4585, page S85, XP009157337 [X] 1-21 * abstract *-
SEARCH- SCHILLING S ET AL, "Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, (20060701), vol. 145, no. 1, doi:10.1111/J.1365-2249.2006.03094.X, ISSN 0009-9104, pages 101 - 107, XP009105979 [X] 1-21 * abstract *
SEARCH- SCHIMRIGK S ET AL, "Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study", EUROPEAN JOURNAL OF NEUROLOGY, (200606), vol. 13, no. 6, ISSN 1351-5101, pages 604 - 610, XP002496537 [X] 1-21 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents